1354 studies found for:    "Chronic lymphocytic leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Chronic lymphocytic leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin;   Drug: cyclophosphamide;   Biological: ofatumumab;   Procedure: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: protein expression analysis
2 Active, not recruiting Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Hematopoietic/Lymphoid Cancer;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: carfilzomib;   Other: Cytokine Assessment;   Other: Pharmacodynamic Studies;   Other: Proteosome Inhibition Assessment;   Other: Pharmacogenomic Studies
3 Terminated Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: alvocidib;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Recruiting Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: pneumococcal polyvalent vaccine;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Not yet recruiting Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Dietary Supplement: curcumin;   Dietary Supplement: cholecalciferol;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Terminated Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine Hydrochloride;   Biological: Alemtuzumab
7 Completed Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: apolizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
9 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Active, not recruiting Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Drug: vorinostat
11 Completed Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: apolizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Completed Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: alvocidib;   Other: laboratory biomarker analysis
13 Active, not recruiting Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: alvocidib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Biological: rituximab;   Drug: cyclophosphamide
14 Terminated
Has Results
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Conditions: Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Intervention: Drug: sorafenib tosylate
15 Completed
Has Results
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Active, not recruiting Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: rituximab;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: lenalidomide;   Other: laboratory biomarker analysis
17 Active, not recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
18 Completed
Has Results
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: rituximab;   Drug: fludarabine phosphate
19 Completed Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Waldenström Macroglobulinemia
Intervention: Drug: alvocidib
20 Active, not recruiting Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Radiation: tositumomab and iodine I 131 tositumomab;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years